| 前收盘价格 | 340.62 |
| 收盘价格 | 339.63 |
| 成交量 | 381,106 |
| 平均成交量 (3个月) | 997,600 |
| 市值 | 13,289,267,200 |
| 市盈率 (P/E TTM) | 74.75 |
| 预期市盈率 (P/E Forward) | 66.67 |
| 价格/销量 (P/S) | 10.18 |
| 股市价格/股市净资产 (P/B) | 9.88 |
| 52周波幅 | |
| 利润日期 | 22 Apr 2026 |
| 营业毛利率 | 3.41% |
| 营业利益率 (TTM) | 12.45% |
| 稀释每股收益 (EPS TTM) | 1.09 |
| 季度收入增长率 (YOY) | 16.30% |
| 季度盈利增长率 (YOY) | 256.50% |
| 总债务/股东权益 (D/E MRQ) | 18.19% |
| 流动比率 (MRQ) | 6.30 |
| 营业现金流 (OCF TTM) | 179.16 M |
| 杠杆自由现金流 (LFCF TTM) | 135.83 M |
| 资产报酬率 (ROA TTM) | 5.82% |
| 股东权益报酬率 (ROE TTM) | 3.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | Penumbra, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.50 |
|
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.64% |
| 机构持股比例 | 91.96% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baillie Gifford & Co | 31 Dec 2025 | 876,325 |
| Rtw Investments, Lp | 31 Dec 2025 | 866,499 |
| Clearbridge Investments, Llc | 31 Dec 2025 | 690,814 |
| Champlain Investment Partners, Llc | 31 Dec 2025 | 601,804 |
| Artisan Partners Limited Partnership | 31 Dec 2025 | 594,112 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 388.00 (Needham, 14.58%) | 购买 |
| 中 | 374.00 (10.44%) | |
| 低 | 349.00 (BTIG, 3.06%) | 保留 |
| 平均值 | 371.46 (9.69%) | |
| 总计 | 4 购买, 9 保留 | |
| 平均价格@调整类型 | 342.12 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Evercore ISI Group | 26 Feb 2026 | 360.00 (6.31%) | 购买 | 341.94 |
| Canaccord Genuity | 20 Jan 2026 | 374.00 (10.44%) | 保留 | 355.44 |
| 17 Dec 2025 | 359.00 (6.01%) | 购买 | 309.26 | |
| RBC Capital | 20 Jan 2026 | 374.00 (10.44%) | 保留 | 355.44 |
| BTIG | 16 Jan 2026 | 349.00 (3.06%) | 保留 | 350.78 |
| Baird | 16 Jan 2026 | 374.00 (10.44%) | 保留 | 350.78 |
| Citigroup | 16 Jan 2026 | 374.00 (10.44%) | 保留 | 350.78 |
| 11 Dec 2025 | 350.00 (3.35%) | 购买 | 311.40 | |
| Jefferies | 16 Jan 2026 | 374.00 (10.44%) | 保留 | 350.78 |
| Leerink Partners | 16 Jan 2026 | 374.00 (10.44%) | 保留 | 350.78 |
| Truist Securities | 16 Jan 2026 | 374.00 (10.44%) | 保留 | 350.78 |
| 18 Dec 2025 | 370.00 (9.26%) | 购买 | 315.35 | |
| Wells Fargo | 15 Jan 2026 | 374.00 (10.44%) | 保留 | 350.49 |
| B of A Securities | 05 Jan 2026 | 370.00 (9.26%) | 购买 | 315.00 |
| JP Morgan | 18 Dec 2025 | 370.00 (9.26%) | 购买 | 315.35 |
| Needham | 17 Dec 2025 | 388.00 (14.58%) | 购买 | 309.26 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合